Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is withdrawing approval of 28 abbreviated new drug applications held by Sun Pharmaceutical Industries, Inc. (Sun Pharmaceutical), U.S. Agent for Sun Pharmaceutical Industries Limited, 270 Prospect Plains Rd., Cranbury, NJ 08512. The drug products are no longer marketed, and Sun Pharmaceutical has requested that the approval of the applications be withdrawn.
January 19, 2017.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601.
End Further Info
Start Supplemental Information
The applications listed in the table in this document are no longer marketed, and Sun Pharmaceutical has requested that FDA withdraw approval of the applications. The company has also, by its request, waived its opportunity for a hearing.
|065007||Cephalexin Capsules USP, Equivalent to (EQ) 250 milligrams (mg) base and EQ 500 mg base.|
|065016||Amoxicillin Capsules USP, 250 mg and 500 mg.|
|065021||Amoxicillin Tablets USP (Chewable), 125 mg and 250 mg.|
|065059||Amoxicillin Tablets USP, 500 mg and 875 mg.|
|065060||Amoxicillin Tablets USP (Chewable), 200 mg and 400 mg.|
|065081||Cephalexin for Oral Suspension USP, EQ 125 mg base/5 milliliters (mL) and EQ 250 mg base/5 mL.|
|065082||Cefpodoxime Proxetil for Oral Suspension USP, EQ 50 mg base/5 mL and EQ 100 mg base/5 mL.|
|065083||Cefpodoxime Proxetil Tablets USP, EQ 100 mg base and EQ 200 mg base.|
|Start Printed Page 92822|
|065102||Amoxicillin and Clavulanate Potassium Tablets USP, 875 mg/EQ 125 mg base.|
|065109||Amoxicillin and Clavulanate Potassium Tablets USP, 500 mg/EQ 125 mg base.|
|065113||Amoxicillin for Oral Suspension USP, 200 mg/5 mL and 400 mg/5 mL.|
|065115||Cefadroxil for Oral Suspension USP, EQ 125 mg base/5 mL, EQ 250 mg base/5 mL, and EQ 500 mg base/5 mL.|
|065118||Cefuroxime Axetil Tablets USP, EQ 125 mg base, EQ 250 mg base, and EQ 500 mg base.|
|065132||Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/EQ 28.5 mg base per 5 mL and 400 mg/EQ 57 mg base per 5 mL.|
|065161||Amoxicillin and Clavulanate Potassium Tablets USP (Chewable), 200 mg/EQ 28.5 mg base and 400 mg/EQ 57 mg base.|
|065207||Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 600 mg/EQ 42.9 mg base per 5 mL.|
|065323||Cefuroxime Axetil for Oral Suspension USP, EQ 125 mg base/5 mL and EQ 250 mg base/5 mL.|
|074975||Acyclovir Capsules USP, 200 mg.|
|074980||Acyclovir Tablets USP, 400 mg and 800 mg.|
|075132||Ranitidine Tablets USP, EQ 75 mg base.|
|075439||Ranitidine Tablets USP, EQ 150 mg base and EQ 300 mg base.|
|076041||Sotret (isotretinoin) Capsules USP, 10 mg, 20 mg, and 40 mg.|
|076285||Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg.|
|076332||Fluconazole for Oral Suspension, 10 mg/mL and 40 mg/mL.|
|076409||Nefazodone Hydrochloride Tablets USP, 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg.|
|076503||Sotret (isotretinoin) Capsules USP, 30 mg.|
|076606||Gabapentin Capsules USP, 100 mg, 300 mg, and 400 mg.|
|076739||Fosinopril Sodium and Hydrochlorothiazide Tablets USP, 10 mg/12.5 mg and 20 mg/12.5 mg.|
Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research, by the Commissioner, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn, effective January 19, 2017.
End Supplemental Information
Dated: December 15, 2016.
Associate Commissioner for Policy.
[FR Doc. 2016-30623 Filed 12-19-16; 8:45 am]
BILLING CODE 4164-01-P